TYRA | tickerfilter.com

Fundamental analysis

16%

Profitability 0%

Dept financing 26%

Liquidity 50%

Performance 20%

Company vs Stock growth

N/A

17.150 9.660

-7.490 -43.67%

+ Add row to compare

Performance

5 Days

-8.79%

1 Month

-30.51%

3 Months

-53.55%

6 Months

-66.84%

1 Year

-58.59%

2 Year

-51.81%

Key data

Stock price

$7.06

P/E Ratio

0.00

DAY RANGE

$6.96 - $7.88

EPS

-$1.10

52 WEEK RANGE

$6.96 - $29.60

52 WEEK CHANGE

-$53.98

MARKET CAP

703.382 M

YIELD

N/A

SHARES OUTSTANDING

52.806 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.88

PUBLIC FLOAT

AVERAGE 10 VOLUME

$436,329

AVERAGE 30 VOLUME

$363,380

Company detail

CEO: Todd J. Harris
Region: US
Website: tyra.bio
Employees: 20
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Tyra Biosciences, Inc. focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.

TYRA - Tyra Biosciences, Inc.